BMS's daclatasvir is first in class to garner CHMP nod
This article was originally published in Scrip
Bristol-Myers Squibb's daclatasvir has been given a positive opinion by the panel that recommends on new drugs in the EU as a treatment for hepatitis C in combination with other therapies. Daclatasvir (under the brand name Daklinza) is the first NS5A complex inhibitor to receive a positive opinion. However, it cannot afford to rest on its laurels, as strong rivals are not far behind.
You may also be interested in...
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.
See how much the CEOs and R&D heads of the world’s biggest pharma companies get paid, and how those companies are performing.